$TNGX — a 92% ORR turned pancreatic cancer into a real bet

$TNGX · Tango Therapeutics Inc · by Thomas Bouman · covered since August 12, 2026

Tango's vopimetostat + daraxonrasib combo posted a 92% ORR in MTAP-deleted pancreatic cancer, now heading into Phase 3. $1B cash funds the run, but the signal is still early-cohort, not confirmed.

The Thesis (The Story)

The approach

Tango is a precision oncology company built around a concept called synthetic lethality: finding cancers with a specific genetic weak point and exploiting it. Its target is MTAP-deleted cancers, a gene deletion found in roughly 10-15% of solid tumors that creates that exploitable weakness. The lead drug, vopimetostat, is a once-daily pill that blocks an enzyme called PRMT5, which these MTAP-deleted cancer cells depend on more heavily than normal cells do.

The pancreatic cancer signal

In June 2026, Tango reported that pairing vopimetostat with Revolution Medicines' daraxonrasib (a RAS-targeting drug) produced a 92% response rate in previously treated patients with MTAP-deleted, RAS-mutant pancreatic cancer, against a historical response rate closer to 15-20% for standard second-line treatment in this disease. That result is now driving a larger, front-line Phase 3 trial in pancreatic cancer.

What else is coming

Two more readouts are due in the second half of 2026: lung cancer data on vopimetostat alone, and the first data on a second drug, TNG456, in glioblastoma (brain cancer). Management has also narrowed the rest of the pipeline, shelving two earlier-stage programs and halting a third, to concentrate spending on this PRMT5-focused approach.

🐂 Bull Case (What has to go right?)

• The 92% response rate and 90% six-month progression-free survival in pancreatic cancer hold up in a larger, randomized Phase 3 trial
• The lung cancer and glioblastoma data due in the second half of 2026 give the company a second and third potential value driver beyond pancreatic cancer alone
• $1.0B in cash after the June 2026 raise funds operations well past the key 2026-2027 readouts, lowering the near-term risk of another dilutive raise
• The MTAP-deletion biomarker works as a built-in patient-selection tool across several other cancer types (bladder, lung, mesothelioma, glioblastoma), so one validated approach could extend into multiple diseases
• Pairing a PRMT5 drug with a RAS-targeting drug positions Tango alongside Revolution Medicines' RAS franchise rather than in competition with it, in a disease (pancreatic cancer) with almost no good treatment options today

🐻 Bear Case (What are the risks?)

• The headline 92% response rate comes from a small group of previously treated patients as of a May 2026 data cutoff, a promising early signal, not proven efficacy, the real test is the larger randomized Phase 3 trial
• The quarterly net loss widened to $55.3M, with R&D spend up to $37.2M and no partnership revenue coming in since a prior collaboration deal lapsed in 2025, spending is accelerating right as the rest of the pipeline gets cut back
• The June 2026 capital raise issued 21.2M new shares plus warrants, real dilution has already happened, and companies funding a Phase 3 trial often need to raise again before the pivotal data reads out
• Narrowing the pipeline cuts optionality, this is now largely a single-mechanism, two-drug story, with less to fall back on if either one disappoints
• Glioblastoma remains one of the hardest cancers to treat successfully, the TNG456 data is still completely unseen heading into the second half of 2026

Conclusion

Tango is a real re-rating candidate if the pancreatic cancer combination data holds up in the larger Phase 3 trial, the gap over historical second-line response rates is wide enough to matter even after accounting for the small early cohort. The June data is a strong early signal, not confirmed proof, until the randomized numbers are in. The glioblastoma and lung data due in the second half of 2026 are what would turn this from a single pancreatic cancer story into a broader, multi-drug franchise, that's the thesis to track from here.

Developments